ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2127

Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

Maya Swaminathan1, Sarah Holt2, John Gore2, Yaw Nyame2, Jonathan Wright2, George Schade2, Ami Shah3, Jeffrey Sparks4, Una Makris5, Petros Grivas6, Maria Suarez-Almazor7, Sarah Psutka2 and Namrata Singh8, 1University of Washington, Seattle, WA, 2Department of Urology, University of Washington, Seattle, WA, 3Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 4Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, 7MD Anderson Cancer Center, Houston, TX, 8University of Washington, Bellevue, WA

Meeting: ACR Convergence 2023

Keywords: Aging, Comorbidity, Mortality, Oncology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have examined the outcomes following a bladder cancer diagnosis in patients with RA. RA is also associated with an increased risk of frailty. Bladder cancer is the second most common urologic cancer with a mean age of diagnosis of 73 years and a high burden of frailty and comorbidity. Importantly, among patients with bladder cancer, frailty is associated with an increased risk of mortality. We sought to evaluate associations between RA and all-cause and cancer-specific mortality in older adults with bladder cancer, adjusted for frailty.

Methods: In this retrospective cohort study, using the Surveillance Epidemiology and End Results cancer registry and linked Medicare claims data (SEER-Medicare), we included patients ³65 years old with incident bladder cancer diagnosed between 2004 and 2017. Patients with a pre-existing diagnosis of RA were identified based on the presence of ³2 ICD-10 codes ≥ 30 days and < 365 days apart. A validated claims-based Frailty Index (Kim et al. 20172) and National Cancer Institute (NCI) Comorbidity Index were derived from claims in the 12 months prior to bladder cancer diagnosis. Patients with a frailty score > 0.2 were categorized as frail. Separate Cox proportional hazards regression models evaluated the association between RA and frailty and 1) overall mortality and 2) bladder cancer-specific mortality, after adjusting for demographics, socioeconomic status, comorbidities, cancer stage, and receipt of guideline-directed bladder cancer treatment per stage. We evaluated the interaction between RA and frailty and performed stratified analyses by frailty status.

Results: We identified 99,418 patients with bladder cancer of whom 1751 (1.8%) had pre-existing RA (Table 1). Among patients with RA, 923 (52.7%) were frail while 33,518 (34.3%) of patients without RA were frail (p< 0.0001).Median follow-up for survivors overall was 5.3 years (interquartile range, IQR, 2.8-8.8) during which time 61,499 patients died. The 5-year overall survival was 73.0% versus 71.9% for patients with and without RA respectively (p< 0.0001) and was 73.0% versus 68.6% for patients with and without frailty (p=0.0001).Among non-frail patients, RA was associated with an increased risk of cancer-specific (aHR 1.22, 95% CI 1.07 – 1.41) and overall mortality (aHR 1.18, 95% CI 1.08-1.29) (Table 2). However, among frail patients, RA was not associated with an increased risk of cancer-specific (aHR 0.92, 95% CI 0.82 – 1.05) or overall mortality (aHR 0.97, 95% CI 0.90-1.04).

Conclusion: RA was associated with a higher risk of bladder cancer-specific and overall mortality in non-frail pts with bladder cancer. Limitations of our study include retrospective nature, potential selection bias, and unmeasured confounding. Our hypothesis-generating results support further evaluation of the association between RA, frailty, and survival in older adults with bladder cancer.

Supporting image 1

Table 1: Demographic and clinical characteristics of patients with bladder cancer with rheumatoid arthritis

Supporting image 2

Table 2: Cox regression model for mortality among older adults with bladder cancer stratified by frailty status.


Disclosures: M. Swaminathan: None; S. Holt: None; J. Gore: None; Y. Nyame: None; J. Wright: None; G. Schade: None; A. Shah: Arena Pharmaceuticals, 5, Eicos Sciences, 5, Kadmon Corporation, 5, Medpace LLC, 5; J. Sparks: AbbVie, 2, Amgen, 2, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 2, 5, Gilead, 2, Inova Diagnostics, 2, Janssen, 2, Optum, 2, Pfizer, 2, ReCor, 2; U. Makris: None; P. Grivas: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Pfizer, 2, Roche, 2; M. Suarez-Almazor: Celgene, 1, Eli Lilly, 2, Pfizer, 2, Syneos Health, 1; S. Psutka: None; N. Singh: None.

To cite this abstract in AMA style:

Swaminathan M, Holt S, Gore J, Nyame Y, Wright J, Schade G, Shah A, Sparks J, Makris U, Grivas P, Suarez-Almazor M, Psutka S, Singh N. Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/associations-between-rheumatoid-arthritis-frailty-status-and-mortality-in-older-adults-with-bladder-cancer/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-rheumatoid-arthritis-frailty-status-and-mortality-in-older-adults-with-bladder-cancer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology